Clinical efficacy of leuprorelin combined with mifepristone in the treatment of endometriosis
10.3760/cma.j.issn.1008-6706.2019.19.021
- VernacularTitle: 亮丙瑞林联合米非司酮治疗子宫内膜异位症的临床观察
- Author:
Liping WANG
1
;
Xiaofang JIN
1
;
Xiaohong WANG
2
Author Information
1. Department of Pharmacy, Hengdian Wenrong Hospital of Dongyang, Dongyang, Zhejiang 322118, China
2. Department of Gynaecology and Obstetrics, Hengdian Wenrong Hospital of Dongyang, Dongyang, Zhejiang 322118, China
- Publication Type:Journal Article
- Keywords:
Endometriosis;
Estradiol;
Luteinizing hormone;
Follicle stimulating hormone, human;
Leuprorelin;
Mifepristone
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(19):2395-2399
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of leuprorelin combined with mifepristone in the treatment of endometriosis.
Methods:From September 2014 to September 2016, 168 cases of endometriosis were selected in the research.The patients were divided into the control group and the research group according to the random number table method, with 84 patients in each group.All patients underwent laparoscopic endometrial debridement with fertility preservation.The control group was treated with mifepristone, while the study group was treated with combination of leuprorelin and mifepristone.The incidence of adverse drug reactions during treatment was observed, the levels of serum E2, LH, FSH, EmAb and CA125 were detected before and after treatment, the curative effect after treatment was evaluated, and the recurrence and pregnancy of endometriosis within 12 months after treatment were followed.
Results:During the treatment, the incidence rate of adverse drug reactions in the study group(17/84, 20.24%) had no statistically significant difference compared with the control group (13/84, 15.48%) (χ2=0.649, P=0.420). The levels of serum estradiol (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH), anti-endometrial antibody (EmAb) and carbohydrate antigen 125 (CA125) in the two groups were significantly lower than those before treatment (t=17.694, 13.271, 7.943, 4.315, 10.029, 7.952, 14.231, 10.610, 27.953, 22.436, all P<0.001), and the indicators in the study group were significantly lower than those in the control group (t=5.217, 3.859, 3.526, 4.337, 6.048, all P<0.001). The total effective rate of the study group (96.43%) was significantly higher than that of the control group (83.33%) (χ2=7.919, P=0.005). Within 12 months after treatment, the recurrence rate of endometriosis in the study group (2.38%) was significantly lower than that of the control group (15.48%), while the rate of pregnancy (48.81%) was significantly higher than that of the control group(27.38%), there were statistically significant differences between the two groups (χ2=8.858, 8.178; P=0.003, 0.004).
Conclusion:Compared with leuprorelin treatment alone, leuprorelin combined with mifepristone can significantly reduce the serum levels of E2, LH, FSH, EmAb and CA125 in patients with endometriosis, and improve the overall treatment of endometriosis, reduce recurrence, promote pregnancy, and has high safety.
